Sarm1 enzyme activity inhibitor and application thereof
US-2024368168-A1 · Nov 7, 2024 · US
Treatment of cancer with tor kinase inhibitors
US2016008356A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016008356-A1 |
| Application number | US-201414770861-A |
| Country | US |
| Kind code | A1 |
| Filing date | Feb 27, 2014 |
| Priority date | Feb 28, 2013 |
| Publication date | Jan 14, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are methods for treating or preventing a neuroendocrine tumor of non-gut origin in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a neuroendocrine tumor of non-gut origin.
First claim
Opening claim text (preview).
1 . A method for treating a neuroendocrine tumor of non-gut origin, comprising administering an effective amount of a TOR kinase inhibitor of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), or (III) to a patient having a neuroendocrine tumor of non-gut origin. 2 . The method of claim 1 , wherein the neuroendocrine tumor of non-gut origin is a bronchial neuroendocrine tumor, or a neuroendocrine tumor with origin in an organ above the diaphragm. 3 . The method of claim 1 , wherein the neuroendocrine tumor with origin in an organ above the diaphragm is a laryngeal neuroendocrine tumor, a pharyngeal neuroendocrine tumor or a thyroid neuroendocrine tumor. 4 . The method of claim 1 , wherein the neuroendocrine tumor of non-gut origin is a symptomatic endocrine producing tumor or a nonfunctional tumor. 5 . The method of claim 1 , wherein the neuroendocrine tumor of non-gut origin is locally unresectable, metastatic moderate, well differentiated, low (grade 1) or intermediate (grade 2). 6 . A method for achieving complete response, partial response or stable disease, as determined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in a patient, comprising administering an effective amount of a TOR kinase inhibitor of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), or (III) to a patient having a neuroendocrine tumor of non-gut origin. 7 . A method for improving, Eastern Cooperative Oncology Group Performance Status (ECOG) in a patient, comprising administering an effective amount of a TOR kinase inhibitor of formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (II), or (III) to a patient having a neuroendocrine tumor of non-gut origin. 8 . The method of claim 1 , wherein the TOR kinase inhibitor is a compound from Table A, B, or C. 9 . The method of claim 6 , wherein the TOR kinase inhibitor is a compound from Table A, B, or C. 10 . The method of claim 7 , wherein the TOR kinase inhibitor is a compound from Table A, B, or C.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
specific for metastasis · CPC title
- A61K31/4985Primary
Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016008356A1 cover?
- Provided herein are methods for treating or preventing a neuroendocrine tumor of non-gut origin in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a neuroendocrine tumor of non-gut origin.
- Who is the assignee on this patent?
- Signal Pharm Llc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4985. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Jan 14 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).